Jordanova et al (2008) and Gao et al (2007) et al found a no effect of CD4+, but a negative effect of FoxP3+ in univariate analysis in cervical and hepatocellular cancer, respectively. However, only Jordanova carried out multivariate analysis, in which this effect did not hold. The remaining studies observe a prognostic effect of neither CD4+ nor FoxP3+ in esophageal, gastric, ovarian, and renal cell cancer (Sato et al, 2005; Li et al, 2009; Shen et al, 2010; Zingg et al, 2010). This evidence concerns the gene CD4 and renal cell adenocarcinoma.